**Abstract**

***Objective*:** The persistent deficits of social behaviors in mice exposed to social defeat stress as juveniles are useful for studying the pathogenesis of psychiatric disorders following the adverse childhood experiences. In the present study, we investigated a strategy for treating in deficits of social behaviors induced by exposure to social defeat stress as juveniles.

***Methods*:** The juvenile male C57BL/6J mice were exposed to a male aggressive ICR mouse during 1 or 10 consecutive days. Mice were acutely administered desipramine (a noradrenaline reuptake inhibitor), sertraline (a selective serotonin reuptake inhibitor), aripiprazole (a dopamine receptor partial agonist), and memantine \[a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist\] on 1 day after the last exposure to social defeat stress. Administration of desipramine, sertraline, and aripiprazole were also continued once a day for 15 days. We assessed social behaviors at 1 and 15 days after the last exposure to the stress. Monoamine turnover and phosphorylation of NMDA receptor subunits were determined in some brain regions of mice exposed to the stress.

***Results*:** Acute and repeated administration of desipramine, sertraline, and aripiprazole did not attenuate deficits of social behaviors in mice exposed to stress as juveniles. Co-administration of aripiprazole with sertraline repeatedly and administration of memantine acutely showed a tendency and significant, respectively, to attenuate deficits of social behaviors. Utilization of serotonin/dopamine and the phosphorylated protein levels of NR2A were decreased and increased, respectively, in some brain regions of mice showing deficits of social behaviors.

***Conclusion*:** These findings suggest that social defeat stress as juveniles induces the development of antidepressant-treatment-resistant deficits of social behaviors related to monoaminergic and/or glutamatergic dysfunction. Serotonergic and dopaminergic activators or glutamatergic inhibitors may be a strategy for treating to attenuate the treatment-resistant deficits.
